AbbVie
ABBV
$261.72
+0.67%
AbbVie is a global biopharmaceutical company focused on immunology, oncology, neuroscience, and aesthetics, with key products including Skyrizi, Rinvoq, Humira, and Botox. As a top-tier pharma player, it has successfully navigated the Humira patent cliff by pivoting to next-generation therapies and strategic acquisitions like Allergan, Cerevel, and ImmunoGen. The current investor narrative centers on post-Humira growth acceleration, driven by Skyrizi and Rinvoq, alongside pipeline expansion in weight-loss and immunology through deals like the $10.9 billion Apogee acquisition. The stock recently hit a 52-week high, reflecting optimism about its growth trajectory and dividend sustainability, though valuation concerns are emerging.…
ABBV
AbbVie
$261.72
Related headlines
Investment Opinion: Should I buy ABBV Today?
Rating: Buy. AbbVie is a high-quality pharma with accelerating growth, a strong pipeline, and a reasonable forward valuation. The consensus Buy rating and average target of $276.59 support this view, with 8.26% upside.
Sign up to view all
ABBV 12-Month Price Forecast
AbbVie's growth acceleration and reasonable forward valuation make it an attractive investment. The main risks are financial leverage and pipeline execution, but current momentum and analyst sentiment support a bullish stance. I would upgrade to high confidence if Skyrizi/Rinvoq growth exceeds 15% and pipeline milestones are met, or downgrade if earnings fail to recover or dividend is cut.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on AbbVie's 12-month outlook, with a consensus price target around $276.59 and implied upside of +5.7% versus the current price.
Average Target
$276.59
0 analysts
Implied Upside
+5.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$200 - $328
Analyst target range
AbbVie has coverage from 29 analysts, with a consensus recommendation of 'Buy' (mean rating of 1.68 on a 1-5 scale). The average price target is $276.59, implying an upside of 8.26% from the current price of $255.48. The target range spans from $200 (low) to $328 (high), with the high target suggesting a 28.4% upside, reflecting optimism about pipeline success and growth. Recent ratings from major firms like UBS, BMO, and Wells Fargo have been positive, with no downgrades, indicating strong institutional confidence. The wide spread between low and high targets (128 points) highlights uncertainty around pipeline execution and competitive dynamics, but the overall bullish sentiment is supported by the stock's recent momentum and strategic acquisitions.
Drowning in data?
Find the real signal!
Bulls vs Bears: ABBV Investment Factors
AbbVie presents a compelling post-Humira growth story with strong revenue acceleration and robust cash flow, but faces valuation and financial leverage concerns. The bull case is supported by forward P/E near historical lows and analyst optimism, while the bear case highlights elevated trailing multiples and high payout ratio. Currently, the bull case has stronger evidence given the growth trajectory and reasonable forward valuation. The key tension is whether Skyrizi/Rinvoq growth and pipeline success can sustain the premium valuation, or if earnings volatility and debt levels will undermine investor confidence.
Bullish
- Skyrizi and Rinvoq driving growth: Q1 2026 revenue grew 12.43% YoY to $15.0B, with Skyrizi ($4.48B) and Rinvoq ($2.12B) offsetting Humira's decline. These next-gen immunology drugs are the core of the post-Humira growth story.
- Strong free cash flow generation: Trailing twelve-month free cash flow is $20.87B, providing ample capacity for dividends, buybacks, and M&A. This supports the company's ability to invest in growth while returning capital.
- Reasonable forward valuation: Forward P/E of 15.69x is near the lower end of its 5-year range (14.8x-306x), suggesting the market expects normalized earnings. This is attractive for a company with accelerating growth.
- Analyst consensus is Buy: 29 analysts rate ABBV a Buy with a mean rating of 1.68, and the average price target of $276.59 implies 8.26% upside. Recent ratings from UBS, BMO, and Wells Fargo are positive with no downgrades.
Bearish
- Elevated trailing P/E and negative equity: Trailing P/E is 96.41x due to depressed Q1 2026 earnings, and debt-to-equity is -21.12 (negative equity from buybacks). This signals financial leverage and earnings volatility.
- High payout ratio strains dividend: Payout ratio is 275.84%, meaning dividends exceed earnings, funded by debt or cash reserves. This is unsustainable long-term unless earnings rebound sharply.
- Premium valuation on sales and EV/EBITDA: P/S ratio of 6.63x and EV/EBITDA of 26.61x are above industry averages, indicating the market is paying a premium. Any growth disappointment could trigger multiple compression.
- Dependence on pipeline execution: Growth relies heavily on Skyrizi/Rinvoq and new drugs from acquisitions. If pipeline trials fail or competition intensifies, growth could stall, justifying the wide analyst target range ($200-$328).
ABBV Technical Analysis
AbbVie is in a strong uptrend, with the stock up 22.87% over the past year and currently trading at $255.48, near the top of its 52-week range (52-week high of $267.47, low of $190.75). The price sits at 95.5% of the 52-week range, indicating robust momentum and investor confidence, though this also suggests the stock may be overextended in the short term. The 3-month change of +17.34% significantly outperforms the S&P 500's +1.7%, highlighting relative strength, while the 1-year relative strength of +4.31% confirms sustained outperformance.
Beta
0.28
0.28x market volatility
Max Drawdown
-19.2%
Largest decline past year
52-Week Range
$191-$267
Price range past year
Annual Return
+23.5%
Cumulative gain past year
| Period | ABBV Return | S&P 500 |
|---|---|---|
| 1m | +6.8% | +1.0% |
| 3m | +16.4% | +1.1% |
| 6m | +13.7% | +13.8% |
| 1y | +23.5% | +19.5% |
| ytd | +14.1% | +12.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ABBV Fundamental Analysis
AbbVie's revenue is growing steadily, with Q1 2026 revenue of $15.0 billion, up 12.43% year-over-year, driven by strong performance from Skyrizi ($4.48 billion) and Rinvoq ($2.12 billion), which are offsetting Humira's decline ($688 million). The company's gross margin remains high at 71.88%, and operating margin is 31.56%, reflecting efficient cost management. Net income for Q1 2026 was $699 million, a significant drop from prior quarters due to one-time charges, but the trailing twelve-month free cash flow of $20.87 billion demonstrates robust cash generation. The balance sheet shows a debt-to-equity ratio of -21.12 (negative equity due to buybacks), but interest coverage of 6.6x and a current ratio of 0.67 indicate manageable liquidity, though the company relies on debt financing for acquisitions.
Quarterly Revenue
$15.0B
2026-03
Revenue YoY Growth
+12.4%
YoY Comparison
Gross Margin
71.9%
Latest Quarter
Free Cash Flow
$20.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ABBV Overvalued?
Given positive net income, the trailing P/E ratio is 96.41x, which is elevated due to depressed earnings in Q1 2026, while the forward P/E of 15.69x suggests the market expects a strong earnings rebound. The P/S ratio of 6.63x is above the industry average, indicating a premium valuation. Compared to the sector, AbbVie trades at a significant premium on trailing earnings, but the forward P/E is more reasonable, reflecting expected growth. Historically, the stock's P/E has ranged from 14.8x to 306x over the past five years, and the current forward multiple is near the lower end, suggesting the market is pricing in normalized earnings power. The PEG ratio is negative due to negative earnings growth, but the EV/EBITDA of 26.61x is above historical averages, indicating the market is paying up for growth.
PE
96.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 15x~139x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
26.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high debt load with a debt-to-equity ratio of -21.12 (negative equity), though interest coverage of 6.6x is manageable. The payout ratio of 275.84% indicates dividends exceed earnings, funded by debt or cash, which could be cut if earnings don't recover. Q1 2026 net income dropped to $699M due to one-time charges, causing EPS volatility, but free cash flow of $20.87B provides a cushion. Revenue concentration in immunology (Skyrizi, Rinvoq) is a risk if competition or pricing pressures emerge.
FAQ
Key risks include: 1) Financial risk from high debt and negative equity, though interest coverage is adequate. 2) Competitive risk from new immunology drugs that could erode Skyrizi/Rinvoq market share. 3) Macro risk from interest rate changes affecting growth stock valuations. 4) Company-specific risk of pipeline failures or dividend cuts due to the high payout ratio. The most severe risk is a dividend cut, which could trigger a sell-off.
The 12-month forecast is moderately bullish. The base case (50% probability) targets $260-$290, aligning with the average analyst target. The bull case (30%) targets $290-$328, driven by strong growth and pipeline success. The bear case (20%) targets $200-$230, if growth disappoints. The most likely scenario is the base case, assuming continued Skyrizi/Rinvoq growth and no major setbacks.
ABBV is fairly valued on a forward basis but appears overvalued on trailing metrics. The trailing P/E of 96.41x is inflated due to one-time charges, while the forward P/E of 15.69x is near the lower end of its historical range. The P/S ratio of 6.63x is above the industry average, indicating a premium, but the market is pricing in strong growth. Overall, the valuation is reasonable if growth continues as expected.
Yes, ABBV is a good buy for investors with a medium-to-long-term horizon. The stock offers 8.26% upside to the average analyst target of $276.59, with a forward P/E of 15.69x, which is reasonable for its growth rate. The main risk is the high payout ratio, but strong free cash flow supports the dividend. It's particularly suitable for those seeking growth and income, but investors should be aware of potential volatility from pipeline news.
ABBV is best suited for long-term investment, given its growth trajectory and dividend income. The stock has a beta of 0.28, indicating low volatility, and a dividend yield of 2.88%, making it a stable holding. Short-term trading is possible given recent momentum, but the company's value lies in its multi-year growth story. A minimum holding period of 3-5 years is recommended to capture the full benefit of pipeline developments and earnings growth.
